These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 9716291)

  • 1. Comparative safety of teicoplanin and vancomycin.
    Wilson AP
    Int J Antimicrob Agents; 1998 May; 10(2):143-52. PubMed ID: 9716291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Teicoplanin-induced hypersensitivity syndrome with a preceding vancomycin-induced neutropenia: a case report and literature review.
    Hsiao SH; Chen HH; Chou CH; Lin WL; Liu Yeh PY; Wu TJ
    J Clin Pharm Ther; 2010 Dec; 35(6):729-32. PubMed ID: 21054466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative safety of teicoplanin and vancomycin.
    Wood MJ
    J Chemother; 2000 Nov; 12 Suppl 5():21-5. PubMed ID: 11131960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycopeptide-induced vasculitis--cross-reactivity between vancomycin and teicoplanin.
    Marshall C; Street A; Galbraith K
    J Infect; 1998 Jul; 37(1):82-3. PubMed ID: 9733391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolerability of teicoplanin in 117 hospitalized adults with previous vancomycin-induced fever, rash, or neutropenia: a retrospective chart review.
    Hung YP; Lee NY; Chang CM; Lee HC; Wu CJ; Chen PL; Lee CC; Chung CH; Ko WC
    Clin Ther; 2009 Sep; 31(9):1977-86. PubMed ID: 19843487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The comparative efficacy and safety of teicoplanin and vancomycin.
    Cobo J; Fortún J
    J Antimicrob Chemother; 1996 Dec; 38(6):1113-4. PubMed ID: 9023665
    [No Abstract]   [Full Text] [Related]  

  • 7. The comparative efficacy and safety of teicoplanin and vancomycin.
    Wood MJ
    J Antimicrob Chemother; 1996 Feb; 37(2):209-22. PubMed ID: 8707731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of the safety profile of teicoplanin.
    Davey PG; Williams AH
    J Antimicrob Chemother; 1991 Apr; 27 Suppl B():69-73. PubMed ID: 1829079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy and safety of vancomycin versus teicoplanin in febrile neutropenic patients receiving hematopoietic stem cell transplantation.
    Kato-Hayashi H; Niwa T; Ohata K; Harada S; Matsumoto T; Kitagawa J; Tsurumi H; Suzuki A
    J Clin Pharm Ther; 2019 Dec; 44(6):888-894. PubMed ID: 31373043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Red-man syndrome after vancomycin: potential cross-reactivity with teicoplanin.
    Khurana C; de Belder MA
    Postgrad Med J; 1999 Jan; 75(879):41-3. PubMed ID: 10396588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Teicoplanin versus vancomycin for proven or suspected infection.
    Cavalcanti AB; Goncalves AR; Almeida CS; Bugano DD; Silva E
    Cochrane Database Syst Rev; 2010 Jun; (6):CD007022. PubMed ID: 20556772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A closer look at vancomycin, teicoplanin, and antimicrobial resistance.
    Zeckel ML
    J Chemother; 1997 Oct; 9(5):311-31; discussion 332-5. PubMed ID: 9373787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case of hypersensitivity syndrome to both vancomycin and teicoplanin.
    Kwon HS; Chang YS; Jeong YY; Lee SM; Song WJ; Kim HB; Kim YK; Cho SH; Kim YY; Min KU
    J Korean Med Sci; 2006 Dec; 21(6):1108-10. PubMed ID: 17179696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High risk of cross-reactivity between vancomycin and sequential teicoplanin therapy.
    Hsiao SH; Chou CH; Lin WL; Lee EJ; Liao LH; Chang HJ; Yeh PY; Lin CY; Wu TJ
    J Clin Pharm Ther; 2012 Jun; 37(3):296-300. PubMed ID: 22017186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absence of "red man syndrome" in patients being treated with vancomycin or high-dose teicoplanin.
    Rybak MJ; Bailey EM; Warbasse LH
    Antimicrob Agents Chemother; 1992 Jun; 36(6):1204-7. PubMed ID: 1384423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The comparative costs of vancomycin treatment versus teicoplanin in osteoarticular infection caused by methicillin-resistant staphylococci].
    Pham Dang C; Gouin F; Touchais S; Richard C; Potel G
    Pathol Biol (Paris); 2001 Sep; 49(7):587-96. PubMed ID: 11642024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fever, rash, and pancytopenia following vancomycin rechallenge in the presence of ceftazidime.
    Shahar A; Berner Y; Levi S
    Ann Pharmacother; 2000 Feb; 34(2):263-4. PubMed ID: 10676837
    [No Abstract]   [Full Text] [Related]  

  • 18. An audit of efficacy and toxicity of teicoplanin versus vancomycin in febrile neutropenia: is the different toxicity profile clinically relevant?
    Hahn-Ast C; Glasmacher A; Arns A; Mühling A; Orlopp K; Marklein G; Von Lilienfeld-Toal M
    Infection; 2008 Feb; 36(1):54-8. PubMed ID: 18193385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis.
    Svetitsky S; Leibovici L; Paul M
    Antimicrob Agents Chemother; 2009 Oct; 53(10):4069-79. PubMed ID: 19596875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A risk-benefit assessment of teicoplanin in the treatment of infections.
    de Lalla F; Tramarin A
    Drug Saf; 1995 Nov; 13(5):317-28. PubMed ID: 8785019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.